Korea Exchange postpones decision on delisting Kolon TissueGene Results of Phase 3 clinical trial in U.S. likely to be key to resumption of stock trading
Translated by Kim So-in 공개 2022-02-10 08:06:25
이 기사는 2022년 02월 10일 08:01 thebell 에 표출된 기사입니다.
The Korea Exchange (KRX), South Korea's bourse operator, has decided to postpone its decision on whether to delist the scandal-ridden drugmaker Kolon TissueGene from the secondary Kosdaq market.A Kosdaq market committee under the KRX decided on Monday to reopen the review meeting, without giving the reason and timeframe.
“We expect the patient dosing in the Phase 3 clinical trial in the U.S. will be completed in 2023,” said an official at Kolon TissueGene. “We have resumed patient dosing on December 28, 2021 despite the Covid-19 pandemic.”
Last year, Kolon TissueGene was given a one-year grace period by the Kosdaq committee for the second time to restore its credibility over phony reporting of its gene therapy drug Invossa and avoid delisting from the Kosdaq market. The trading of Kolon TissueGene stock has been suspended since 2019.
Upon the committee’s latest call, the final decision will be made in September or October, with the drugmaker’s submission of additional document.
Kolon TissueGene is required to submit an improvement plan and an expert’s verification on the plan within 15 business days from the expiry date of August 31. The KRX will hold a corporate review committee within 29 business days from the document submission date and make the final decision.
Whether the company will be delisted depends on the results of the Phase 3 clinical trial in the U.S. The key to the resumption of the trading is whether Kolon TissueGene can submit a statistically significant Phase 3 clinical trial interim results to the KRX. (Reporting by Sook Hong)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- [방산기업 국산화율 톺아보기]LIG넥스원, 첨단기술·국산화율 90%의 '양립'
- [IPO 모니터]'거버넌스 바꾼' HNS하이텍, 코스닥 이전 성공할까
- [IPO 모니터]메가존클라우드 RFP 마감 'D-3'...제안서 몸값 4조 '유력'
- [IPO 모니터]'콜옵션 딜레마' 빠졌던 이피캠텍 오너, 자금 구했나
- 10년 만에 최대주주 바뀌는 한온시스템, 관전 포인트는
- [IPO 모니터]전진건설로봇, '100% 구주매출' 택한 배경은
- [Market Watch]'한산한' 크레딧 시장, 공사채가 채운다
- '3년만에 등장' DL이앤씨, '주관사+인수단' 대거 확보
- [한국 3대 화랑 경영분석 리포트]가나아트, '한남' 법인 중심 매출 확대 추세
- [한국 3대 화랑 경영분석 리포트]가나아트, 도전정신 물려받은 2세들의 약진